Beta 1 adrenergic receptor Gly389Arg polymorphism and the impact of fixed-dose combination of isosorbide dinitrate/hydralazine in heart failure: Results from the A-HeFT trial

被引：0

|

作者：

McNamara, DM

Tam, SW

Sabolinski, ML

Tobelman, P

Palmer, A

Janosko, K

Feldman, AM

Worcel, M

机构：

[1] NitroMed Inc, Lexington, MA USA

[2] Univ Pittsburgh, Pittsburgh, PA USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2006年 / 47卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：67A / 67A

页数：1

相关论文

共 43 条

[1] Fixed-dose combination of isosorbide dinitrate and hydralazine improves quality of life in African Americans with heart failure: Results from A-HeFT
Carson, P
Ghali, J
Tam, SW
Worcel, M
JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S150 - S150
[2] The benefits of the fixed-dose combination of isosorbide dinitrate and hydralazine in A-HeFT are not influenced by the absence or presence of diabetes
Miller, Alan
Yancy, Clyde W.
Sabofinski, Michael L.
Braman, Virginia M.
Worcel, Manuel
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 44A - 44A
[3] Fixed-dose combination of isosorbide dinitrate and hydralazine reduces heart failure hospitalizations, length of stay, and cost in African-American Heart Failure Trial (A-HeFT)
Linde-Zwirble, WT
Tam, SW
Sabolinski, M
Ghali, J
Villagra, VG
Winkelmayer, WC
Angus, DC
JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S149 - S149
[4] GNB3 TT genotype predicts enhanced benefit of fixed-dose combination of isosorbide dinitrate and hydralazine in African Americans with heart failure: Results of the A-HeFT trial
McNamara, Dennis M.
Tam, S. William
Sabolinski, Michael L.
Tobelmann, Page
Hanley-Yanez, Karen
Janosko, Karen M.
Worcel, Manuel
JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S71 - S71
[5] In-trial economic evaluation of a fixed-dose combination of isosorbide dinitirate and hydralazine in blacks with heart failure: Results from the African-American Heart Failure Trial (A-HeFT)
Linde-Zwirble, WT
Tam, SW
Worcel, M
Sabolinski, ML
Ghali, J
Angus, DC
JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S151 - S151
[6] Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: Results from A-HeFT
Cohn, Jay N.
Tam, William
Anand, Inder S.
Taylor, Anne L.
Sabolfnski, Michael L.
Worcel, Manuel
JOURNAL OF CARDIAC FAILURE, 2007, 13 (05) : 331 - 339
[7] Results of the extension to A-HeFT [X-A-HeFT] support the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine (ISDN/HYD)
Yancy, Clyde W.
Ghali, Jalal K.
Braman, Virginia M.
Sabolinski, Michael L.
Worcel, Manuel
JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S80 - S80
[8] Fixed-dose combination of isosorbide dinitrate and hydralazine inhibits left ventricular remodeling in well-treated severe heart failure in African-Americans: A-HeFT
Cohn, JN
Anand, I
Taylor, A
JOURNAL OF CARDIAC FAILURE, 2005, 11 (09) : 720 - 720
[9] Fixed-dose combination of isosorbide dinitrate and hydralazine inhibits left ventricular remodeling in well-treated severe heart failure in African-Americans: A-HeFT
Cohn, JN
Anand, I
Taylor, A
Tan, SW
CIRCULATION, 2005, 112 (17) : U704 - U704
[10] G protein beta 3 subunit (GNB3) genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: Results of the A-HeFT trial
McNamara, Dennis M.
Tam, S. William
Sabolinski, Michael L.
Tobelmann, Page
Hanley-Yanez, Karen
Janosko, Karen M.
Worcel, Manuel
CIRCULATION, 2006, 114 (18) : 442 - 442

← 1 2 3 4 5 →